Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12199291 | 0.87 | DGKA (0.50) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL407271 | 0.86 | MGLL (0.49) | MGLLADRA2AADRA1AMAPTBLM | |
| SCHEMBL22113257 | 0.83 | ADRA2A (0.42) | MGLLADRA2AADRA1AMAPTBLM | |
| SCHEMBL475320 | 0.82 | ADRA2A (0.52) | MGLLADRA2AADRA1AMAPTBLM | |
| SCHEMBL141329 | 0.81 | DGKA (0.50) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL28146111 | 0.81 | DGKA (0.45) | MGLLADRA2AADRA1AMAPTBLM | |
| SCHEMBL12846426 | 0.81 | TSHR (0.62) | MGLLADRA2AADRA1AMAPTBLM | |
| SCHEMBL28222618 | 0.81 | ALDH1A1 (0.52) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL24465441 | 0.80 | TSHR (0.36) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL26330790 | 0.80 | MGLL (0.37) | MGLLADRA2AADRA1AMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149521-A1 | METHODS OF TREATING VIRAL INFECTIONS USING ARGINASE | BIO CANCER TREAT INTERNATIONAL LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| EP-4005590-A1 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM WITH ARGINASE I | Bio-Cancer Treatment International Ltd. (CN) | 2022-06-01 | — | — | EP | disclosed |
| EP-3137103-B1 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM WITH ARGINASE I | BIO CANCER TREAT INTERNATIONAL LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| US-20200061165-A1 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM WITH ARGINASE I | BIO-CANCER TREATMENT INTERNATIONAL LIMITED (HK) | 2020-02-27 | — | — | US | disclosed |
| US-20180085440-A1 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM WITH ARGINASE I | BIO-CANCER TREATMENT INTERNATIONAL LIMITED (HK) | 2018-03-29 | — | — | US | disclosed |
| US-9867875-B2 | Methods and compositions for modulating the immune system with Arginase I | BIO-CANCER TREATMENT INTERNATIONAL LIMITED (HK) | 2018-01-16 | — | — | US | disclosed |
| US-9789169-B2 | Methods and compositions for modulating the immune system with arginase I | BIO-CANCER TREATMENT INTERNATIONAL LIMITED (HK) | 2017-10-17 | — | — | US | disclosed |
| US-20160367648-A1 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM WITH ARGINASE I | BIO-CANCER TREATMENT INTERNATIONAL LIMITED (HK) | 2016-12-22 | — | — | US | disclosed |
| US-20150315561-A1 | Methods and Compositions for Modulating the Immune System with Arginase I | BIO-CANCER TREATMENT INTERNATIONAL LIMITED (HK) | 2015-11-05 | — | — | US | disclosed |
| US-20120263739-A1 | ANTI INTEGRIN ANTIBODIES LINKED TO NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC AGENTS | MERCK PATENT GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
| US-7037425-B2 | Mesoporous membrane collector and separator for airborne pathogen detection | PURDUE RESEARCH FOUNDATION (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1453591-A4 | MESOPOROUS MEMBRANE COLLECTOR AND SEPARATOR FOR AIRBORNE PATHOGEN DETECTION | PURDUE RESEARCH FOUNDATION (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050277586-A1 | Peptide chemically modified with polyethylene glycol | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1493748-A1 | PEPTIDE CHEMICALLY MODIFIED WITH POLYETHYLENE GLYCOL | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-05 | — | — | EP | disclosed |
| EP-1453591-A1 | MESOPOROUS MEMBRANE COLLECTOR AND SEPARATOR FOR AIRBORNE PATHOGEN DETECTION | PURDUE RESEARCH FOUNDATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030222012-A1 | Mesoporous membrane collector and separator for airborne pathogen detection | PURDUE RESEARCH FOUNDATION (US) | 2003-12-04 | — | — | US | disclosed |
| US-6602952-B1 | Hydrogels, which are cross-linked polymers that swell in water, have potential as drug delivery vehicles | SHEARWATER CORPORATION | 2003-08-05 | — | — | US | disclosed |
| WO-2003049840-A1 | MESOPOROUS MEMBRANE COLLECTOR AND SEPARATOR FOR AIRBORNE PATHOGEN DETECTION | PURDUE RESEARCH FOUNDATION (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1223986-A2 | HYDROGELS DERIVED FROM CHITOSAN AND POLY(ETHYLENE GLYCOL) | Shearwater Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001000246-A2 | HYDROGELS DERIVED FROM CHITOSAN AND POLY(ETHYLENE GLYCOL) | SHEARWATER CORPORATION (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149521-A1 | METHODS OF TREATING VIRAL INFECTIONS USING ARGINASE | ARG1, ARG2, OAT | MGLL 322/4885ADRA2A 3005/4885ADRA1A 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.